A decade-long study of 55,000 cancer patients adds to mounting evidence that anemia drugs such as Amgen’s Epogen and Johnson & Johnson’s Procrit boost the risk of blood clots significantly. Report

Original Source of Study: Anemia meds double clot risk

Who’s at fault for the slow-to-market H1N1 vaccine? USA Today asked consumers, and more than half of them blamed drug companies. Some 62 percent said they blame pharma either a great deal or moderately. The government, by contrast, got 58 percent of the blame. We all know why vaccine…

Novartis is plotting a major advertising campaign to support the launch of its over-the-counter heartburn med Prevacid 24HR. Major as in $200 million worth, the Wall Street Journal reports. The campaign kicks off with TV spots that start airing tomorrow, and it’s designed to aid CEO Daniel Vasella’s diversification…

Yet more debate on whether healthcare reform in the U.S. will help drugmakers, and if so, how much. The industry says not so much. But industry-watching number crunchers tell a different story. PhRMA Chairman (and AstraZeneca chief) David Brennan ( photo ) tells Reuters that “there is not an…

Business reporting is all about numbers–and bigger numbers tend to get more attention. But when it comes to job losses, small numbers can add up to big ones pretty quickly. And for the folks on the receiving end of the cost-cutting axe, it doesn’t matter whether they’re one of…

Now that Merck CEO Dick Clark ( photo )

Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis.

Original Source of Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement

Cosmetic drugs are hot and happening even as the economy limps along–just take a gander at cosmeceuticals specialist Medici’s latest numbers

Simultaneous vaccination against seasonal and pandemic flu provides protection against the virus without provoking significant side effects, according to a clinical study released by GlaxoSmithKline. Report

Original Source of Doubling up on flu shots OK, study shows

It looks as if yet another U.S. drug-marketing investigation is about to be settled. As Dow Jones reports, Forest Laboratories has reached a tentative deal with the feds, which would settle civil allegations that it mismarketed antidepressants and a thyroid drug. But the deal wouldn’t cover the government’s “ongoing…